Skip to main content
Top
Published in: Osteoporosis International 1/2008

01-01-2008 | Short Communication

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

Authors: A. Dovio, D. Generali, M. Tampellini, A. Berruti, S. Tedoldi, M. Torta, S. Bonardi, M. Tucci, G. Allevi, S. Aguggini, A. Bottini, L. Dogliotti, A. Angeli

Published in: Osteoporosis International | Issue 1/2008

Login to get access

Abstract

Summary

The variability of serum osteoprotegerin (OPG) and soluble RANKL (sRANKL) along the 24-h cycle was assessed in 20 healthy women. No rhythmic variations of serum OPG, sRANKL or sRANKL/OPG ratio were detected as a group phenomenon. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL.

Introduction

Physiological bone turnover shows diurnal variations. The aim of the study was to assess variability of OPG and sRANKL serum levels along the 24-h cycle.

Methods

Blood was collected from 20 healthy women (median age 31 years, range 25–65 years) at 4-h intervals between 08:00 and 24:00 and at 2-h intervals between 24:00 and 08:00. Serum albumin, cortisol, osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX), OPG and total sRANKL were measured. Temporal variations were assessed by the COSINOR model.

Results

Circadian rhythms of cortisol and albumin documented a normal synchronization within the circadian structure. Serum OC and CTX showed rhythmic variations, peaking at night-time. Rhythmic variations of serum OPG, sRANKL and sRANKL/OPG ratio were not detected as a group phenomenon. On an individual basis, rhythmic changes were detected in ten patients for OPG and eight patients for sRANKL, with very small amplitudes and heterogeneous acrophases.

Conclusions

The absence of consistent rhythmic variations of circulating OPG and sRANKL levels may reflect the absence of rhythmic variations of their expression in the bone microenvironment. Were this the case, the nocturnal rise of bone resorption should be accounted for by different, not RANKL/OPG-mediated factors. Since circulating OPG and sRANKL may derive from sources other than bone, rhythmicity could be masked by non-rhythmic or non-synchronized rhythmic expression in these sources. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL.
Literature
1.
go back to reference Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495PubMedCrossRef Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495PubMedCrossRef
2.
go back to reference Theoleyre S, Wittrant Y, Tat SK, et al (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457–475PubMedCrossRef Theoleyre S, Wittrant Y, Tat SK, et al (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457–475PubMedCrossRef
3.
go back to reference Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331PubMedCrossRef Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323–6331PubMedCrossRef
4.
go back to reference Dovio A, Data V, Angeli A (2005) Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 28 [10 Suppl]:14–22PubMed Dovio A, Data V, Angeli A (2005) Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 28 [10 Suppl]:14–22PubMed
5.
go back to reference Camacho P, Kleerekoper M (2006) Biochemical markers of bone turnover. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. The American Society for Bone and Mineral Research, Washington, DC, pp 127–132 Camacho P, Kleerekoper M (2006) Biochemical markers of bone turnover. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. The American Society for Bone and Mineral Research, Washington, DC, pp 127–132
6.
go back to reference Heshmati HM, Riggs BL, Burritt MF, et al (1998) Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. J Clin Endocrinol Metab 83:751–756PubMedCrossRef Heshmati HM, Riggs BL, Burritt MF, et al (1998) Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. J Clin Endocrinol Metab 83:751–756PubMedCrossRef
7.
go back to reference Greenspan SL, Dresner-Pollak R, Parker RA, et al (1997) Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 60:419–423PubMedCrossRef Greenspan SL, Dresner-Pollak R, Parker RA, et al (1997) Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 60:419–423PubMedCrossRef
8.
go back to reference Ahmad AM, Hopkins MT, Fraser WD, et al (2003) Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 32:170–179PubMedCrossRef Ahmad AM, Hopkins MT, Fraser WD, et al (2003) Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. Bone 32:170–179PubMedCrossRef
9.
go back to reference Qvist P, Christgau S, Pedersen BJ, et al (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61PubMedCrossRef Qvist P, Christgau S, Pedersen BJ, et al (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61PubMedCrossRef
10.
go back to reference Bjarnason NH, Henriksen EEG, Alexandersen P, et al (2002) Mechanism of circadian variation in bone resorption. Bone 30:307–313PubMedCrossRef Bjarnason NH, Henriksen EEG, Alexandersen P, et al (2002) Mechanism of circadian variation in bone resorption. Bone 30:307–313PubMedCrossRef
11.
go back to reference Henriksen DB, Alexandersen P, Hartmann B, et al (2007) Dissociation of bone resorption and formation by GLP-2. A 14-day study in healthy postmenopausal women. Bone 40:723–729PubMedCrossRef Henriksen DB, Alexandersen P, Hartmann B, et al (2007) Dissociation of bone resorption and formation by GLP-2. A 14-day study in healthy postmenopausal women. Bone 40:723–729PubMedCrossRef
13.
go back to reference Fu L, Patel MS, Bradley A, et al (2005) The molecular clock mediates leptin-regulated bone formation. Cell 122:803–815PubMedCrossRef Fu L, Patel MS, Bradley A, et al (2005) The molecular clock mediates leptin-regulated bone formation. Cell 122:803–815PubMedCrossRef
14.
go back to reference Zvonic S, Ptitsyn AA, Kilroy G, et al (2007) Circadian oscillation of gene expression in murine calvarial bone. J Bone Miner Res 22:357–365PubMedCrossRef Zvonic S, Ptitsyn AA, Kilroy G, et al (2007) Circadian oscillation of gene expression in murine calvarial bone. J Bone Miner Res 22:357–365PubMedCrossRef
16.
go back to reference Tarquini R, Mazzoccoli G, Dolenti S, et al (2005) Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. Biomed Pharmacother 59 [Suppl 1]:225–228CrossRef Tarquini R, Mazzoccoli G, Dolenti S, et al (2005) Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. Biomed Pharmacother 59 [Suppl 1]:225–228CrossRef
17.
go back to reference Ohta H, Onoe Y, Shimizu M, et al (2006) Diurnal and monthly variations in bone metabolic markers and bone metabolic modulators in young women (abstract). J Bone Miner Res 21:144 Ohta H, Onoe Y, Shimizu M, et al (2006) Diurnal and monthly variations in bone metabolic markers and bone metabolic modulators in young women (abstract). J Bone Miner Res 21:144
18.
go back to reference Generali D, Berruti A, Tampellini M, et al (2007) The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. Bone 40:182–188PubMedCrossRef Generali D, Berruti A, Tampellini M, et al (2007) The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. Bone 40:182–188PubMedCrossRef
19.
go back to reference Dovio A, Sartori ML, Angeli A (2002) Correspondence re: A. Lipton et al, Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8:2306–2310, 2002. Clin Cancer Res 9:2384–2385 Dovio A, Sartori ML, Angeli A (2002) Correspondence re: A. Lipton et al, Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8:2306–2310, 2002. Clin Cancer Res 9:2384–2385
20.
go back to reference Chan BYY, Buckley KA, Durham BH, et al (2003) Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kB ligand and osteoprotegerin in plasma and serum. Clin Chem 49:2083–2085PubMedCrossRef Chan BYY, Buckley KA, Durham BH, et al (2003) Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kB ligand and osteoprotegerin in plasma and serum. Clin Chem 49:2083–2085PubMedCrossRef
21.
go back to reference Hawa G, Brinskelle-Schmal N, Glatz K, et al (2003) Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. Clin Lab 49:461–463PubMed Hawa G, Brinskelle-Schmal N, Glatz K, et al (2003) Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. Clin Lab 49:461–463PubMed
22.
go back to reference Srivastava AK, Mohan S, Singer FR, Baylink DJ (2002) A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 31:62–69PubMedCrossRef Srivastava AK, Mohan S, Singer FR, Baylink DJ (2002) A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 31:62–69PubMedCrossRef
23.
24.
go back to reference Blair JM, Zheng Y, Dunstan CR (2007) RANK ligand. Int J Biochem Cell Biol 39:1077–1081 Blair JM, Zheng Y, Dunstan CR (2007) RANK ligand. Int J Biochem Cell Biol 39:1077–1081
25.
go back to reference Nakashima T, Kobayashi Y, Yamasaki S, et al (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768–775PubMedCrossRef Nakashima T, Kobayashi Y, Yamasaki S, et al (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768–775PubMedCrossRef
26.
go back to reference Hikita A, Yana I, Wakeyama H, et al (2006) Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 281:36846–36855PubMedCrossRef Hikita A, Yana I, Wakeyama H, et al (2006) Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 281:36846–36855PubMedCrossRef
27.
go back to reference Tomoyasu A, Goto M, Fujise N, et al (1998) Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 245:382–387PubMedCrossRef Tomoyasu A, Goto M, Fujise N, et al (1998) Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 245:382–387PubMedCrossRef
28.
go back to reference Dovio A, Allasino B, Palmas E, et al (2007) Increased osteoprotegerin levels in Cushing’s syndrome are associated with an adverse cardiovascular risk profile. J Clin Endocrinol Metab 92:1803–1808PubMedCrossRef Dovio A, Allasino B, Palmas E, et al (2007) Increased osteoprotegerin levels in Cushing’s syndrome are associated with an adverse cardiovascular risk profile. J Clin Endocrinol Metab 92:1803–1808PubMedCrossRef
Metadata
Title
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis
Authors
A. Dovio
D. Generali
M. Tampellini
A. Berruti
S. Tedoldi
M. Torta
S. Bonardi
M. Tucci
G. Allevi
S. Aguggini
A. Bottini
L. Dogliotti
A. Angeli
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 1/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-007-0423-z

Other articles of this Issue 1/2008

Osteoporosis International 1/2008 Go to the issue